To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from breast cancer, the authors assessed clinical outcomes and prognostic factors for survival.
The records from 350 consecutive female patients who underwent SRS for 1535 brain metastases from breast cancer were reviewed. The median patient age was 54 years (range 19–84 years), and the median number of tumors per patient was 2 (range 1–18 lesions). One hundred seventeen patients (33%) had a single metastasis to the brain, and 233 patients (67%) had multiple brain metastases. The median tumor volume was 0.7 cm3 (range 0.01–48.9 cm3), and the median total tumor volume for each patient was 4.9 cm3 (range 0.09–74.1 cm3).
Overall survival after SRS was 69%, 49%, and 26% at 6, 12, and 24 months, respectively, with a median survival of 11.2 months. Factors associated with a longer survival included controlled extracranial disease, a lower recursive partitioning analysis (RPA) class, a higher Karnofsky Performance Scale score, a smaller number of brain metastases, a smaller total tumor volume per patient, the presence of deep cerebral or brainstem metastases, and HER2/neu overexpression. Sustained local tumor control was achieved in 90% of the patients. Factors associated with longer progression-free survival included a better RPA class, fewer brain metastases, a smaller total tumor volume per patient, and a higher tumor margin dose. Symptomatic adverse radiation effects occurred in 6% of patients. Overall, the condition of 82% of patients improved or remained neurologically stable.
Stereotactic radiosurgery was safe and effective in patients with brain metastases from breast cancer and should be considered for initial treatment.
Abbreviations used in this paper: ARE = adverse radiation effect; EORTC = European Organisation for Research and Treatment of Cancer; GKS = Gamma Knife surgery; KPS = Karnofsky Performance Scale; MST = median survival time; OS = overall survival; PFS = progression-free survival; RPA = recursive partitioning analysis; RTOP = Radiation Therapy Oncology Group; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy.
* Drs. Kondziolka and Kano contributed equally to this work.
Address correspondence to: Douglas Kondziolka, M.D., Department of Neurological Surgery, University of Pittsburgh, Suite B-400, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213. email: email@example.com.
Please include this information when citing this paper: published online October 1, 2010; DOI: 10.3171/2010.8.JNS10461.
AndrewsDWScottCBSperdutoPWFlandersAEGasparLESchellMC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet363:1665–16722004
AoyamaHShiratoHTagoMNakagawaKToyodaTHatanoK: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA295:2483–24912006
Barnholtz-SloanJSSloanAEDavisFGVigneauFDLaiPSawayaRE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol22:2865–28722004
ChangELWefelJSHessKRAllenPKLangFFKornguthDG: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol10:1037–10442009
CoxJDStetzJPajakTF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys31:1341–13461995
FrazierJLBatraSKaporSVellimanaAGandhiRCarsonKA: Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys76:1486–14922009
GasparLScottCRotmanMAsbellSPhillipsTWassermanT: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys37:745–7511997
JawaharAShayaMCampbellPAmpilFWillisBKSmithD: Role of stereotactic radiosurgery as a primary treatment option in the management of newly diagnosed multiple (3–6) intracranial metastases. Surg Neurol64:207–2122005
Mahmoud-AhmedASSuhJHLeeSYCrownoverRLBarnettGH: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys54:810–8172002
SerizawaTHiguchiYOnoJMatsudaSNaganoOIwadateY: Gamma Knife surgery for metastatic brain tumors without prophylactic whole-brain radiotherapy: results in 1000 consecutive cases. J Neurosurg105:Suppl86–902006
SneedPKSuhJHGoetschSJSanghaviSNChappellRBuattiJM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys53:519–5262002